The new report* shows that CF patients in the US are more likely to live well into adulthood compared to several decades ago, and expect a median survival age of 37 years, showing a dramatic improvement of over the last 25 years.
The CF patient population’s average survival age in the US has steadily increased due to early diagnosis and treatment with all 50 states screening for CF in newborns. As a result of this stringency, the National Cystic Fibrosis Patient Registry reported that 75.7% of patients with CF suffered no medical complications.
Similarly to the other markets, Spain’s median age of death has increased in CF patients, with early screening and detection resulting in earlier treatment. The most common cause of CF-related death in Spain is respiratory failure, but improved treatment, lung transplants, and nutrition control is successfully tackling this problem.
In comparison, Germany boasts a relatively low crude mortality rate compared with most countries, but GlobalData believes that this may be due to CF deaths being underreported, undiagnosed, or undertreated.
For Sample Pages, please click or add the below link to your browser:
Chronic lung disease CF is caused by the defective cystic fibrosis transmembrane conductance regulator (CFTR) gene, which is more common in Caucasian populations and leads to thick, sticky mucus accumulating in the respiratory, digestive, and reproductive systems. Lung disease is the primary cause of death in CF patients, as the organs become susceptible to bacterial infections and inflammation, leading to respiratory failure.
CF is widespread throughout the world, but is most common across the US and Europe. The World Health Organization (WHO) states that CF occurs in one in 2,000–3,000 births in the European Union (EU) and one in 3,500 births in the US. In comparison, African-Americans have a CF prevalence of one in
15,000. The UK and France have the highest prevalence proportion of CF, suggesting that CF-causing mutations originate from British and French ancestry, though the US has the largest disease population, with approximately 30,000 people affected by the disorder.
However, diagnosed cases of CF have recently been increasing in Latin America, the Middle East, and the Indian subcontinent, likely due to the emigration of Western Europeans to these regions.
GlobalData forecasts that total prevalent cases of CF in individuals in the 0–35 year age group will grow from 58,056 in 2012 to 68,373 in 2022, at an average annual growth rate of 1.78%.
This report provides an overview of the risk factors and comorbidities associated with cystic fibrosis, as well as global trends in prevalence in the six major markets (the US, France, Germany, Italy, Spain, and the UK). It also includes a 10-year epidemiological forecast of prevalent cases of cystic fibrosis segmented by sex, age, and mutation type.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.
GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.
For further details, please click or add the below link to your browser:
Visit our report store: http://www.globaldata.com/
For more details contact:
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782